Evidence map›Paper›PMID 34108119›Full record

ArticleJournal of the Formosan Medical Association = Taiwan yi zhi2021

Economic evaluation for mass vaccination against COVID-19.

Wei-Chun Wang, Jean Ching-Yuan Fann, Ray-E Chang, Ya-Chung Jeng, Chen-Yang Hsu, Hsiu-Hsi Chen, Jin-Tan Liu, Amy Ming-Fang Yen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Formosan Medical Association = Taiwan yi zhi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei-Chun WangInstitute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Jean Ching-Yuan FannDepartment of Health Industry Management, School of Healthcare Management, Kainan University, Taoyuan, Taiwan.
Ray-E ChangInstitute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan.
Ya-Chung JengSchool of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
Chen-Yang HsuInstitute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; Dachung Hospital, Miaoli, Taiwan.
Hsiu-Hsi ChenInstitute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
Jin-Tan LiuDepartment of Economics, National Taiwan University, Taipei, Taiwan.
Amy Ming-Fang YenSchool of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address: amyyen@tmu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccine is supposed to be the most effective means to prevent COVID-19 as it may not only save lives but also reduce productivity loss due to resuming pre-pandemic activities. Providing the results of economic evaluation for mass vaccination is of paramount importance for all stakeholders worldwide.

methodsWe developed a Markov decision tree for the economic evaluation of mass vaccination against COVID-19. The effectiveness of reducing outcomes after the administration of three COVID-19 vaccines (BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and AZD1222 (Oxford-AstraZeneca)) were modelled with empirical parameters obtained from literatures. The direct cost of vaccine and COVID-19 related medical cost, the indirect cost of productivity loss due to vaccine jabs and hospitalization, and the productivity loss were accumulated given different vaccination scenarios. We reported the incremental cost-utility ratio and benefit/cost (B/C) ratio of three vaccines compared to no vaccination with a probabilistic approach.

resultsModerna and Pfizer vaccines won the greatest effectiveness among the three vaccines under consideration. After taking both direct and indirect costs into account, all of the three vaccines dominated no vaccination strategy. The results of B/C ratio show that one dollar invested in vaccine would have USD $13, USD $23, and USD $28 in return for Moderna, Pfizer, and AstraZeneca, respectively when health and education loss are considered. The corresponding figures taking value of the statistical life into account were USD $176, USD $300, and USD $443.

conclusionMass vaccination against COVID-19 with three current available vaccines is cost-saving for gaining more lives and less cost incurred.

Indexed as

COVID-19Mass VaccinationBNT162 VaccineChAdOx1 nCoV-19Cost-Benefit AnalysisCOVID-19 VaccinesHumansBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesCost-benefit analysisCost-utility analysisCOVID-19VaccineValue of statistical life

Identifiers

PMID34108119
PMCPMC8148613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.